Award Number: W81XWH-11-1-0639

TITLE: Development of Pain Endpoint Models for Use in Prostate Cancer Clinical Trials and Drug Approval

PRINCIPAL INVESTIGATOR: Dr. Ethan Basch

CONTRACTING ORGANIZATION: University of North Carolina at Chapel Hill Chapel Hill, NC, 27599

REPORT DATE: October 2017

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Add regeneration of the add region	REPORT DOCUMENTATION PAGE					Form Approved			
adar useba do longenge consequences in the second determined. Set consequences and use of the second in called and determined in updates and the second and determined and	Public reporting burden for this collection of information is estimated to average 1 hour per response including the time for reviewing instrum					UNB INO. 0704-0188			
Line: Developed in table 2 wave and table and participation of the set of th	data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing								
Interport DATE 1.0 DATES COVERED October 2017 Annual 3.0 DATES COVERED 4. TITLE AND SUBTITLE: 30 SEP 2016 – 29 SEP 2017 5a. CONTRACT NUMBER 30 SEP 2016 – 29 SEP 2017 4. TITLE AND SUBTITLE: 30 SEP 2016 – 29 SEP 2017 5a. CONTRACT NUMBER 30 SEP 2016 – 29 SEP 2017 5a. CONTRACT NUMBER working and the set of the se	4302. Respondents should be	aware that notwithstanding a	ny other provision of law, no person	n shall be subject to any penalty f	or failing to comply with	a collection of information if it does not display a currently			
October 2017 Annual 30 SEP 2016 - 29 SEP 2017 ATTLE AND SUBTLE: Soc CONTRACT NUMBER Development of Pain Endpoint Models for Use in Prostate Cancer Clinical Trials and Drug Approval 56. GRANT NUMBER 6. AUTHOR(S) 56. FRANT NUMBER Eithan Basch, MD ebasch@med.unc.edu 56. TASK NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 57. TASK NUMBER University of North Carolina at Chapel Hill, North Carolina, 27599 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSORMONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release: Distribution Unlimited 11. SPONSORMONITOR'S ACRONYM(S) 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxach-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal the study work described in Aim 2 has been publisheand cancere stubils for a pain endpoint model which can be used i	1. REPORT DATE	LEASE DO NOT RETORN TO	2. REPORT TYPE	1233.	3. D	ATES COVERED			
4: TITLE AND SUBTITLE: Development of Pain Endpoint Models for Use in Prostate Cancer Clinical Trials and Drug Approval 5a. CONTRACT NUMBER 4: TITLE AND SUBTITLE: Development of Pain Endpoint Models for Use in Prostate Cancer Clinical Trials and Drug Approval 5a. CONTRACT NUMBER 6: AUTHOR(\$) 5b. GRANT NUMBER 6: AUTHOR(\$) 5c. FASK NUMBER 1: Antonia Bennett, PhD ebasch@med.unc.edu 7: PERFORMING ORGANIZATION NAME(\$) AND ADDRESS(E\$) 5c. FASK NUMBER University of North Carolina at Chapel Hill, North Carolina, 27599 6. PERFORMING ORGANIZATION RAME(\$) AND ADDRESS(E\$) 9: SPONSORING / MONTORING AGENCY NAME(\$) AND ADDRESS(E\$) 10. SPONSORMONTOR'S ACRONYM(\$) 11: SPONSORMONTOR'S ACRONYM(\$) 11. SPONSORMONTOR'S ACRONYM(\$) 12: DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release: Distribution Unlimited 11. SPONSORMONTOR'S REPORT NUMBER(\$) 13: SUPELMENTARY NOTES 14. ABSTRACT 0BJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatist prostate cancer receiving adoutes A im 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in privotal drine the SUSOR and Drug Admi	October 2017		Annual		30 3	SEP 2016 – 29 SEP 2017			
Approval Sb. GRAMT NUMBER NUMEER Start Sb. GRAMT NUMBER Start Start Sc. PROGRAM ELEMENT NUMBER Sc. PROGRAM ELEMENT NUMBER Sc. Antionia Bennett, PhD avbenn@email.unc.edu 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Sc. PREFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of North Carolina at Chapel Hill 450 Sc. PREFORMING ORGANIZATION REPORT West Drive, 3rd Floor, CB# 2795 Chapel Hill, North Carolina, 27599 10. SPONSOR/MONITOR'S ACCONYM(S) S. SAMT Medical Research and Material Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACCONYM(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxl-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study desig	4. TITLE AND SUBTIT Development of Pa	LE: ain Endpoint Models	for Use in Prostate Canc	er Clinical Trials and D	rug 5a. (CONTRACT NUMBER			
Rel XWH-11-0639 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(\$) 5d. PROJECT NUMBER Ethan Basch, MD Antonia Bennett, PhD avbenn Bemail.unc.edu 5d. PROJECT NUMBER 7. PERFORMING ORGANIZATION NAME(\$) AND ADDRESS(E\$) University of North Carolina at Chapel Hill, North Carolina, 27599 8. PERFORMING ORGANIZATION REPORT NUMBER 9. SPONSORING / MONITORING AGENCY NAME(\$) AND ADDRESS(E\$) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(\$) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(\$) 13. SUPPLEMENTARY NOTES 14. ABSTRACT 0CBLCTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrater-resistant metastatic prostate cancer receiving doctaxel-based chemotherapy, in order to establish key design effements of a pain endpoint model which can be used in pivotal trial. SUMMARY: We report the following progress: (1) the study designed to address Air 1 is accruing patients at all four sites; (2) an manuscript resulting from the work described to Air 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from wor	Approval				5b.	GRANT NUMBER			
5. PROGRAM ELEMENT NUMBER 6. AUTHOR(5) Ethan Basch, MD ebasch @med.unc.edu Antonia Bennett, PhD avbenn @email.unc.edu 7. PERFORMING ORGANIZATION NAME(5) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT University of North Carolina at Chapel Hill 450 West Drive, 374 Floor, CB# 2795 8. PERFORMING ORGANIZATION REPORT 9. SPONSORING / MONTORING AGENCY NAME(5) AND ADDRESS(ES) 10. SPONSORMONITOR'S ACRONYM(5) 11. SPONSORMONITOR'S ACRONYM(5) 11. SPONSORMONITOR'S REPORT NUMBER(5) 11. SPONSORMONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 11. SPONSORMONITOR'S REPORT 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorus, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxl-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials that are feasible, methodologically rigorus, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic					W81	LXWH-11-1-0639			
6. AUTHOR(\$) 5. PROJECT NUMBER Ethan Basch, MD ebasch@med.unc.edu Antonia Bennett, PhD avbenn@email.unc.edu 7. PERFORMING ORGANIZATION NAME(\$) AND ADDRESS(E\$) avbenn@email.unc.edu University of North Carolina at Chapel Hill 450 8. PERFORMING ORGANIZATION REPORT West Drive, 3rd Floor, CB# 2795 Chapel Hill, 8. PERFORMING ORGANIZATION REPORT S. SPONSORING / MONITORING AGENCY NAME(\$) AND ADDRESS(E\$) 10. SPONSORMONITOR'S ACRONYM(\$) U.S. Arny Medical Research and Materiel Command 11. SPONSORMONITOR'S ACRONYM(\$) Fort Detrick, Maryland 21702-5012 11. SPONSORMONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxeh and is accruing patients at all four sites; (2) a manuscript resulting from the work described in Am 2 has been published bit work described in Am 2 has been published bit work described in Am 2 has been published by the journal Cancer, timelit from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from tor work describ					5c. I	PROGRAM ELEMENT NUMBER			
Ethan Basch, MD ebasch@med.unc.edu 5e. TASK NUMBER Antonia Bennett, PhD avbenn@email.unc.edu 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(5) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT University of North Carolina at Chapel Hill 450 8. PERFORMING ORGANIZATION REPORT West Drive, 3rd Floor, CB# 2795 Chapel Hill, 10. SPONSORING / MONITORING AGENCY NAME(5) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command 10. SPONSOR/MONITOR'S ACRONYM(5) Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(6) 12. DISTRIBUTION / AVAILABILITY STATEMENT 7. PONSOR/MONITOR'S REPORT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain enpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcoti	6. AUTHOR(S)				5d.	PROJECT NUMBER			
Antonia Bennett, PhD avbenn@email.unc.edu 57. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT University of North Carolina at Chapel Hill 450 8. PERFORMING ORGANIZATION REPORT West Drive, 3rd Floor, CB# 2795 Chapel Hill, 9. PERFORMING ORGANIZATION REPORT 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 12. STRIBUTION / AVAILABILITY STATEMENT 11. SPONSOR/MONITOR'S REPORT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer ceiving docetaxel-based chemotherapy, in order to establish key designel enerts of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European UriOgy</i> , titled "Effects of Cabo22 antinition Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort' and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Paliliation Measurement in Cancer Clinical Tr	Ethan Basch MD	ebasch@r	med unc edu		5e. ⁻	TASK NUMBER			
11.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1	Antonia Bennett	PhD avbenn@e	mail unc edu						
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER University of North Carolina at Chapel Hill, North Carolina, 27599 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S ACRONYM(S) 12. Namy Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabocantinib on Pain and Narcotic USe in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 2 has been published by the journal	/ intonia Definica, i				5f. V	5f. WORK UNIT NUMBER			
In the database of white Naturation instructor, the Reconserved of Section 1. Inversity of North Carolina at Chapel Hill, SO University of North Carolina, 27599 In SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) In SPONSORING / MONITOR'S ACRONYM(S) 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) In SPONSORING / MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) In SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES In SPONSOR/MONITOR'S REPORT NUMBER(S) 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which cas be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in Aim 3 has been published by the journal Cancer, titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscript shave been attached to annual report submitted to Department of Defenses in November 2015. 18. NAME OF RESPONSIBLE PERSON USAMENC <td< td=""><td></td><td>SANIZATION NAME</td><td></td><td></td><td>8 P</td><td>EREORMING ORGANIZATION REPORT</td></td<>		SANIZATION NAME			8 P	EREORMING ORGANIZATION REPORT			
University of North Carolina at Chapel Hill 450 West Drive. 3rd Floor, CB# 2795 Chapel Hill, North Carolina, 27599 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in me with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four site; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer, Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal Cancer, filed: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscript resulting from to subject Temms Nothing listed 16. SECURITY CLASSIFICATION OF: U.U. 17. LIMITATION 18. NUMBER 19. NUMBER (include server LOW 13			AND ADDICESS(ES)		N N	NUMBER			
West Drive, 3rd Floor, CB# 2795 Chapel Hill, North Carolina, 27599 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) libed manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS 19a. NAME OF RESPONSIBLE PERSON USAMMENC Nothing listed 10. 1	University of North	Carolina at Chap	el Hill 450						
North Carolina, 27599 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACCONYM(S) U.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in me with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Unology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , "Ittled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses	West Drive, 3rd Fl	oor, CB# 2795 Ch	apel Hill,						
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscript shave been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS 17. LIMITATION OF ABSTRACT 18. N	North Carolina, 27	599							
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S ACRONYM(S) Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castraton-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS 17. LIMITATION OF ABSTRACT 19a. NAME OF RESP									
9. SPONSORING / MONITORING AGENCY NAME(5) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 11. SPONSOR/MONITOR'S REPORT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS 17. LIMITATION OF ABSTRACT 18a.									
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS Nothing listed 16. SECURITY CLASSIFICATION OF: 17. LIMITATION U 18. NUMBER U 19. ALME OF RESPONSIBLE PERSON USAMRMC a. REPORT U	9. SPONSORING / MC	NITORING AGENCY	NAME(S) AND ADDRES	S(ES)	10. 5	SPONSOR/MONITOR'S ACRONYM(S)			
Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohot" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS 17. LIMITATION U 18. NUMBER UU 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT U b. ABSTRACT U c. THIS PAGE U 13	U.S. Army Medica	Research and M	ateriel Command						
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TEMS Nothing listed 16. SECURITY CLASSIFICATION OF: 17. LIMITATION U 18. NUMBER OF PAGES U 19a. NAME OF RESPONSIBLE PERSON USAMRMC. a. REPORT U b. ABSTRACT U 17. LIMITATION U 18. 19a. NAME OF RESPONSIBLE PERSON USAMRMC. <	Fort Detrick, Mary	and 21/02-5012							
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON USAMRMC. 19. TELEPHONE NUMBER (include aree) 13					11.3	SPONSOR/MONITOR'S REPORT			
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 19a. NAME OF RESPONSIBLE PERSON USAMEMC 16. SECURITY CLASSIFICATION OF: 17. LIMITATION U 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMEMC 13. 13. 13.						NOMBER(3)			
Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS Nothing listed 16. SECURITY CLASSIFICATION OF: U U U U U U U U 13.	12 DISTRIBUTION / A	VAILABILITY STATE	MENT						
13. SUPPLEMENTARY NOTES 14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 19. NAME OF RESPONSIBLE PERSON 16. SECURITY CLASSIFICATION OF: U U 13. U U 13.	Approved for Publ	ic Release; Distrib	ution Unlimited						
14. ABSTRACT OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic User in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT U U 13	13. SUPPLEMENTAR	Y NOTES							
OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON USAMRMC a. REPORT U U U 13									
OBJECTIVE: The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE UU 13	14. ADSTRACT								
progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS Nothing listed 16. SECURITY CLASSIFICATION OF: U U U 13	OBJECTIVE: Th	e obiective of thi	s work is to establis	sh standard metho	ds for measu	ring pain palliation and pain			
requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS Nothing listed a. REPORT U U U 13 b. ABSTRACT C. THIS PAGE U U U 13	progression in pr	ostate cancer cl	inical trials that are	feasible, methodo	logically rigo	rous, and meet regulatory			
longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS Nothing listed 16. SECURITY CLASSIFICATION OF: U U U U 13 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code)	requirements for	drug approval a	nd labeling. The pri	imary aim of this a	ward is to co	nduct an observational			
initial initial data in the database residue in the database provides of the control for the control of the co	longitudinal stud	v in men with ca	strate-resistant met	astatic prostate ca	ancer receivin	nd docetaxel-based			
trials. SUMMARY: We report the following progress: (1) the study designed to address Aim 1 is accruing patients at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS Nothing listed 16. SECURITY CLASSIFICATION OF: U U U U 13 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code)	chemotherany in	n order to establ	ish kay dasian alam	ents of a nain end	noint model	which can be used in nivotal			
at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS Nothing listed 16. SECURITY CLASSIFICATION OF: U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U </td <td colspan="7">the nonnerapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal</td>	the nonnerapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal								
at an out sites, (2) a manuscript resulting from the work described in Aim 2 has been published in the journal <i>European Urology</i> , titled: "Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS Nothing listed 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U	thats. Solviniviant 1. we report the following progress. (1) the study designed to address Aim 1 is accruing patients								
Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal Cancer, titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS Nothing listed a. REPORT U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U	at all four sites; (2) a manuscript resulting from the work described in Aim 2 has been published in the journal								
Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS Nothing listed 16. SECURITY CLASSIFICATION OF: 0 0 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON USAMRMC 0 0 0 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. ABSTRACT c. THIS PAGE UU 13	European Orolog	<i>jy,</i> illed: Ellecis			ic Use in Pati	ents with Castration-resistant			
work described in Aim 3 has been published by the journal Cancer, titled: "Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS Nothing listed 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 13 13	Prostate Cancer	Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort" and (3) the manuscript resulting from							
Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS Nothing listed 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 0F PAGES 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U U 13	work described in Aim 3 has been published by the journal <i>Cancer</i> , titled: "Pain Palliation Measurement in Cancer								
annual report submitted to Department of Defenses in November 2015. 15. SUBJECT TERMS Nothing listed 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE UU 13 19b. TELEPHONE NUMBER (include area code)	Clinical Trials: The US Food and Drug Administration Perspective." Both manuscripts have been attached to								
15. SUBJECT TERMS Nothing listed 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT a. REPORT b. ABSTRACT U U U U U U U U IIII D IIIII D IIIIII D IIIIII D IIIII D IIIIII D IIIIII D IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	annual report submitted to Department of Defenses in November 2015.								
Nothing listed 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE 19a. NAME OF RESPONSIBLE PERSON USAMRMC U U U UU 13	15. SUBJECT TERMS								
16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT 18. NUMBER OF RESPONSIBLE PERSON USAMRMC a. REPORT b. ABSTRACT c. THIS PAGE UU U U U UU 10 10 UU 13	Nothing listed								
a. REPORT U U U U U U U U U U U U U U U U U U U	16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC			
U U U UU 13	a. REPORT	b. ABSTRACT	c. THIS PAGE	1		19b. TELEPHONE NUMBER (include area			
13	U	U	U	UU		code)			
					12				
					13				

TABLE OF CONTENTS

KEYWORDS4OVERALL PROJECT SUMMARY4KEY RESEARCH ACCOMPLISMENTS9CONCLUSIONS10PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS10INVENTIONS, PATENTS AND LICENSES11REPORTABLE OUTCOMES11OTHER ACHIEVEMENTS11REFERENCES11APPENDICES12	INTRODUCTION	4
OVERALL PROJECT SUMMARY4KEY RESEARCH ACCOMPLISMENTS9CONCLUSIONS10PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS10INVENTIONS, PATENTS AND LICENSES11REPORTABLE OUTCOMES11OTHER ACHIEVEMENTS11REFERENCES11APPENDICES12	KEYWORDS	4
KEY RESEARCH ACCOMPLISMENTS.9CONCLUSIONS10PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS10INVENTIONS, PATENTS AND LICENSES11REPORTABLE OUTCOMES11OTHER ACHIEVEMENTS11REFERENCES11APPENDICES12	OVERALL PROJECT SUMMARY	4
CONCLUSIONS10PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS10INVENTIONS, PATENTS AND LICENSES11REPORTABLE OUTCOMES11OTHER ACHIEVEMENTS11REFERENCES11APPENDICES12	KEY RESEARCH ACCOMPLISMENTS	9
PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS10INVENTIONS, PATENTS AND LICENSES11REPORTABLE OUTCOMES11OTHER ACHIEVEMENTS11REFERENCES11APPENDICES12	CONCLUSIONS	
INVENTIONS, PATENTS AND LICENSES	PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS	
REPORTABLE OUTCOMES11OTHER ACHIEVEMENTS11REFERENCES11APPENDICES12	INVENTIONS, PATENTS AND LICENSES	11
OTHER ACHIEVEMENTS	REPORTABLE OUTCOMES	11
REFERENCES	OTHER ACHIEVEMENTS	11
APPENDICES	REFERENCES	11
	APPENDICES	

INTRODUCTION

Pain is common in men with metastatic prostate cancer and can substantially impair functioning and quality of life. Regulatory standards for the design of symptom endpoints have evolved substantially over the past decade (culminating in an FDA Guidance document issued on this topic in December 2009), and approaches used previously to assess cancer-related pain and analgesic use are no longer considered sufficiently methodologically rigorous. The objective of this work is to establish standard methods for measuring pain palliation and pain progression in prostate cancer clinical trials that are feasible, methodologically rigorous, and meet regulatory requirements for drug approval and labeling. The primary aim of this award is to conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials. The second aim is to analyze data from a feasibility study of pain assessment nested within an industrysponsored phase II treatment trial conducted in the Prostate Cancer Clinical Trials Consortium. The third aim is to conduct literature reviews and moderate a consensus meeting, with input from investigators in the Prostate Cancer Clinical Trials Consortium, FDA Office of Oncology Drug Products, FDA Study Endpoint and Label Development Team, and FDA Division of Anesthesia, Analgesia and Rheumatology Products, in order to establish discrete guidelines and produce a publication delineating key methodological components of pain studies in prostate cancer.

KEYWORDS

Pain, metastatic castrate resistant prostate cancer, clinical trials, FDA, study endpoints

OVERALL PROJECT SUMMARY

In this section, we report the progress made towards the completion of each Aim.

Aim 1 To conduct an observational longitudinal study in men with castrate-resistant metastatic prostate cancer receiving docetaxel-based chemotherapy, in order to establish key design elements of a pain endpoint model which can be used in pivotal trials.

- The award was originally grant to Memorial Sloan Kettering Cancer Center
- Initial award period 30 SEPT 2011-29 SEPT 2014
- In 2011, Dr. Ethan Basch moved from Memorial Sloan Kettering Cancer Center to University of North Carolina at Chapel Hill
- The award was relinquished by MSKCC to UNC in 2011, but administrative delays prevented Pain Registry study from opening until 2013 (aim 1)
- The second award period was 30 SEPT 2011-29 SEPT 2015
- In AUG 2015 we requested a 30 months no cost extension, as we were currently in progress of obtaining HRPO approval to re-open the study at MSKCC. This was approved on 29 SEPT 2015.
- The current award period is 30 SEPT 2011-31 MARCH 2018

The table below lists Tasks of Aim 1 as outlined in the Statement of Work (PC100563 Basch 7-20-2011, revised 10-7-2016)

Summary of events:

SITE	Date of	Date of	Date of	Date of	Date of	Data	Projected
	Initial IRB	Initial	First	Closure to	Closure to	Analysis	Study
	Approval	HRPO	Enrollment	Accrual	Participant	End	End Date
		Approval			Follow-up	Date	
UNC	29 JAN	15 AUG	23 JAN	31 DEC	30 SEPT	31 MAR	31 MAR
	2013	2013	2014	2016	2017	2018	2018
OHSU	10 MAY	27 AUG	22 APR	29 FEB	28 FEB	NA	28FEB
	2013	2013	2014	2016	2017		2017
JHU	9 MAY	29 AUG	28 MAY	29 FEB	28 FEB	NA	28 FEB
	2013	2013	2014	2016	2017		2017
UW	6 NOV	14 MAR	12 SEPT	29 FEB	28 FEB	NA	28 FEB
	2013	2014	2014	2016	2017		2017
MSKCC	15 JUL	11 NOV	23 DEC	31 DEC	30 SEPT	NA	30 SEPT
	2015	2015	2015	2016	2017		2017

Table 1. Current Status of Tasks Outline in Scope of Work

Task 1. Develop study protocol and obtain IRB approval (Months 1 – 6) IN PROGRESS

1a. Submit Letter of Intent to Prostate Cancer Clinical Trials Consortium (Month 23) Completed – AUG 2013

1b. Elicit input on study design from collaborators (Months 1 - 2) **Completed**

1c. Draft study protocol, including all case report forms (CRFs) (Months 1 - 3) **Completed**

1d. Submit protocol to departmental review committees at UNC (Month 14) **Completed – NOV 2012**

1e. Obtain IRB approval at UNC (Months 19)

Note: Revise protocol to indicate UNC is now coordinating center. Submit for IRB approval at UNC (Month 20). Administrative delays prevented the opening of the study at UNC Chapel Hill until JAN 2013

Completed – JAN 29 2013

1f. Submit for IRB review at participating sites:

SITE	Date of Initial IRB Approval
OHSU	10 MAY 2013
JHU	9 MAY 2013
UW	6 NOV 2013
MSKCC	15 JUL 2015

Completed – JUL 15 2015

1g: Complete the transition of the award from MSKCC (original lead site) to UNC (SEPT 2013, Month 24)

Completed – SEPT 30 2013

1h. Submit each site for HRPO review:

SITE	Initial HRPO Approval Date
UNC	15 AUG 2013
OHSU	27 AUG 2013
JHU	29 AUG 2013
UW	14 MAR 2014
MSKCC	11 NOV 2015

Completed – NOV 11 2015

<u>Task 2. Prepare for data collection and analysis (Months 1 – 6)</u> IN PROGRESS
2a. Develop IVRS platform (Months 1 – 3) Completed
2b. Develop study databases on secure, password-protected server (Months 3 – 6) Completed
2c. Draft statistical analysis plan and elicit feedback from collaborators (Months $1 - 6$) In Progress
Task 3. Implement study protocol (Months 23-60) COMPLETED
3a. Conduct site orientations (Month 25-48) Completed
3b. Recruit and enroll patients (Months 23-61) Completed
 3c. Track accrual/follow-up, conduct weekly telephone meetings with site data managers, and conduct monthly telephone meetings with site PIs (Months 23-75) Completed
<u>Task 4. Analyze study data (Months 23 – 72)</u>
IN PROGRESS 4a. Import data from IVRS to secure study database (Months 23 – 78) Completed
4b. Collect CRFs completed by clinic staff on monthly basis (Months 23 – 73)
Completed
4c. Enter CRF data into secure study database (Months 23 – 78)
4d. Perform data quality audits on monthly basis (Months 23 – 78)
Completed
4e. Analyze data, per SAP, and prepare tables and figures (Months 47 – 78)
In progress 4. Prenare manuscripts and abstracts with input from collaborators (Months 47 – 78)
In progress

The current accrual for each site is as follows:

SITE	Number of	Number of	Consent	Target	% Target	Accrual
	Patients	Patients	Rate %	Accrual	Accrual	Status
	Screened	Enrolled			Reached	
	and					
	Approached					
UNC	52	51	98%	48	106%	CLOSED
MSKCC	38	32	84%	27	119%	CLOSED
OHSU*	65	52	80%	50	104%	CLOSED
JHU*	73	57	78%	65	88%	CLOSED
UW*	40	28	70%	30	93%	CLOSED
TOTAL	268	220	82%	220	100%	

*Sites are closed to accrual as of 29-FEB-2016. Participant follow-up continues until 28-FEB-2017.



All study sites are closed to accrual after reaching the target accrual (N=220). The study has closed follow-up on patients enrolled at JHU, UW, and OHSU as of 28-FEB-2017. Additionally, the study has closed follow-up enrolled patients at UNC and MSKCC, as of 30-SEPT-2017. As stated in the previous annual review, although accrual was slower than originally hoped, follow up and compliance have been higher than anticipated resulting in richer follow-up data and better overview of outcome.

Through the careful work of the project coordinators (Sarah Drier, Philip Carr, and Ryan Brooks) we have strong relationships with the research staff at each of the studies sites. The activities of the study progressed well throughout accrual and follow-up. There were open lines of communication with the sites for the duration to ensure data quality. The renewal of subcontracts and the renewal of IRB approvals (continuing review) is proceeding well at each site. Now that the follow-up period has closed, we have asked sites to remain engaged with the study so that we may obtain additional data or make inquiries during analysis.

Preliminary results of the primary objective were presented at the International Society for Quality of Life Research annual research meeting on October 20, 2017. The citation is below:

Bennett AV, Shouery M, Wang M, Whang YE, Milowsky M, Drier S, Carr P, Morris MJ, Scher HI, Higano CS, Beer TM, Carducci MA, Basch E. *Observational Longitudinal Study of Pain in Men with Metastatic Castrate-Resistant Prostate Cancer: Aim 1. Rates*

of pain palliation and pain progression as indicated by self-reported daily pain and analgesic use. Presentation at International Society for Quality of Life Research 25th Annual Research Meeting, Philadelphia PA, October 20, 2017.

Aim 2 To analyze data from a feasibility study of pain assessment nested within an industry-sponsored phase II treatment trial conducted in the Prostate Cancer Clinical Trials Consortium.

Data analysis from pain assessment nested in a phase II clinical trial of cabozantinib has been analyzed. The manuscript, published by the journal *European Urology*, has been attached to the annual report submitted to Department of Defenses in November 2015.

Basch E, Autio KA, Smith MR, et al: Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. Eur Urol. 2015 Feb;67(2):310-8. doi: 10.1016/j.eururo.2014.02.013. PMID: 24631409

Aim 3 To conduct literature reviews and moderate a consensus meeting, with input from investigators in the Prostate Cancer Clinical Trials Consortium, FDA Office of Oncology Drug Products, FDA Study Endpoint and Label Development Team, and FDA Division of Anesthesia, Analgesia and Rheumatology Products, in order to establish discrete guidelines and produce a publication delineating key methodological components of pain studies in prostate cancer.

A meeting with the relevant stakeholders was held. A manuscript was written with FDA collaboration. This manuscript, published by the journal *Cancer*, has been attached to the annual report submitted to Department of Defenses in November 2015.

Basch E, Trentacosti AM, Burke LB, Kwitkowski V, Kane RC, Autio KA, Papadopoulos E, STansbury JP, Kluetz PG, Smith H, Justice R, Pazdur R. Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective. Cancer, 2014 Mar 1;120(5):761-7. doi: 10.1002/cncr.28470

KEY RESEARCH ACCOMPLISHMENTS

Aim 1. The study is closed to accrual and follow-up at all sites. Accrual at JHU, OHSU, and UW all ended in February 2016 and their follow-up ended in February 2017. Accrual at MSK and UNC closed in December 2016 and follow-up closed in September 2017. Data analysis is underway, and preliminary results of the primary objective have been presented at an annual research meeting.

Aim 2. A study was designed and conducted with an industry sponsor phase II trial. Results were analyzed and manuscript was published in *European Urology* (Basch, Euro Urol 2015) In addition, patient understanding and acceptance of the worst pain NRS was established in this population (Bennett et al, ASCO and ISPOR, 2013). The manuscript and abstracts are included in the Appendix.

Aim 3. A meeting with the relevant stakeholders was held and a manuscript was written with FDA collaboration. This manuscript was been published by the journal *Cancer*. (Basch, Cancer 2014), has been attached to the annual report submitted to Department of Defenses in November 2015.

The findings of Aim 2 and Aim 3 are described below in REPORTABLE OUTCOMES

CONCLUSIONS

The observational longitudinal study (Aim 1) has completed accrual (N=220) and all sites are closed to accrual. Additionally, we have completed follow-up for enrolled patients as of 30-SEPT-2017. We have strong working relationships with each of the sites which will facilitate management of the study and ensure data quality as we complete analysis. As noted in the Summary of Events table, data analysis will be completed by March 31, 2018. Aims 2 and 3 of this project are now complete, with each resulting in a peer-reviewed manuscript published in high impact journals.

PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS

Bennett AV, Shouery M, Wang M, Whang YE, Milowsky M, Drier S, Carr P, Morris MJ, Scher HI, Higano CS, Beer TM, Carducci MA, Basch E. Observational Longitudinal Study of Pain in Men with Metastatic Castrate-Resistant Prostate Cancer: Aim 1. Rates of pain palliation and pain progression as indicated by self-reported daily pain and analgesic use. Presentation at International Society for Quality of Life Research 25th Annual Research Meeting, Philadelphia PA, October 20, 2017.

Basch E, Autio KA, Smith MR, et al: Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. Eur Urol. 2015 Feb;67(2):310-8. doi: 10.1016/j.eururo.2014.02.013. PMID: 24631409

Basch E, Trentacosti AM, Burke LB, Kwitkowski V, Kane RC, Autio KA, Papadopoulos E, STansbury JP, Kluetz PG, Smith H, Justice R, Pazdur R. Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective. Cancer, 2014 Mar 1;120(5):761-7. doi: 10.1002/cncr.28470

Bennett AV, Eremenco S, Heon N, Scheffold C, Schimmoller F, Weitzman AL, Basch E. Mode equivalence of Interactive Voice Response (IVR) and paper versions of the Brief Pain Inventory (BPI) "worst pain" item in metastatic resistant prostate cancer (MCPRC) evaluated conceptually using qualitative methods. International Society for Pharmacoeconomics and Outcomes Research. 16th Annual European Congress, Dublin, Ireland, November 2-6, 2013.

Bennett AV, Atkinson TM, Heon N, O'Keefe B, Scheffold C, Schimoller F, Basch E. Qualitative assessment of the Brief Pain Inventory (BPI) "pain at its worst in the last 24 hours" item to support assessment of pain as a clinical trial endpoint in metastatic castrate resistant prostate cancer (mCRPC) per FDA labeling standards. Abstract. American Society of Clinical Oncology. Chicago IL, June 1-5, 2013.

INVENTIONS, PATENTS AND LICENSES

None

REPORTABLE OUTCOMES

Aim 1 – Research is in progress

Aim 2 – Research findings include:

- 1. Collection of pain data via automated telephone system is feasible in a clinical trial including symptomatic men with advanced metastatic CRPC that is heavily pretreated.
- 2. Tabulation of total analgesic dose is feasible and can be combined with pain intensity data in clinical trial response and definition.
- 3. Content validity of a patient pain diary was established
- 4. Patient understanding and acceptance of the worst pain NRS was established in this population (Bennett et al, ASCO and ISPOR, 2013)
- 5. Related end points including sleep quality and general activity were significantly associated with pain response.
- 6. Results of the phase 2 pain analysis: Cabozantinib demonstrated clinically meaningful pain palliation, reduced or eliminated patients' narcotic use, and improved patient functioning, thus meriting prospective validation in phase 3 studies. (Basch, Euro Urol, 2015)
- 7. Results from this phase II pain assessment served as rationale for design of phase 3 trial with primary pain endpoints.

Aim 3 – Key findings of this paper (Basch, Cancer 2014) include articulations of current FDA thinking about the design end points in cancer trails. This includes:

- 1. Methodological criteria for selective pain measurements
- 2. Approaches for analgesic tabulation
- 3. Approach to demonstrating durability of pain response
- 4. Role of pain end points in drug approval and labeling
- 5. Issues related to pain measurements in open and unblinded trials

OTHER ACHIEVEMENTS

None at this time

REFERENCES

Bennett AV, Shouery M, Wang M, Whang YE, Milowsky M, Drier S, Carr P, Morris MJ, Scher HI, Higano CS, Beer TM, Carducci MA, Basch E. Observational Longitudinal Study of Pain in Men with Metastatic Castrate-Resistant Prostate Cancer: Aim 1. Rates of pain palliation and pain progression as indicated by self-reported daily pain and analgesic use. Presentation at International Society for Quality of Life Research 25th Annual Research Meeting, Philadelphia PA, October 20, 2017.

Basch E, Autio KA, Smith MR, et al: Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. Eur Urol. 2015 Feb;67(2):310-8. doi: 10.1016/j.eururo.2014.02.013. PMID: 24631409

Basch E, Trentacosti AM, Burke LB, Kwitkowski V, Kane RC, Autio KA, Papadopoulos E, STansbury JP, Kluetz PG, Smith H, Justice R, Pazdur R. Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration Perspective. Cancer, 2014 Mar 1;120(5):761-7. doi: 10.1002/cncr.28470. PMID: 24375398

Bennett AV, Atkinson TM, Heon N, O'Keefe B, Scheffold C, Schimoller F, Basch E. Qualitative assessment of the Brief Pain Inventory (BPI) "pain at its worst in the last 24 hours" item to support assessment of pain as a clinical trial endpoint in metastatic castrate resistant prostate cancer (mCRPC) per FDA labeling standards. Abstract. American Society of Clinical Oncology. Chicago IL, June 1-5, 2013.

Bennett AV, Eremenco S, Heon N, Scheffold C, Schimmoller F, Weitzman AL, Basch E. Mode equivalence of Interactive Voice Response (IVR) and paper versions of the Brief Pain Inventory (BPI) "worst pain" item in metastatic resistant prostate cancer (MCPRC) evaluated conceptually using qualitative methods. International Society for Pharmacoeconomics and Outcomes Research. 16th Annual European Congress, Dublin, Ireland, November 2-6, 2013.

APPENDICES

The following manuscripts and abstracts have been attached to the annual report submitted to Department of Defense in October 2017. Please see enclosed PDF at the bottom of this page.

Basch E, Autio KA, Smith MR, et al: Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. Eur Urol. 2015 Feb;67(2):310-8. doi: 10.1016/j.eururo.2014.02.013. PMID: 24631409

Basch E, Trentacosti AM, Burke LB, Kwitkowski V, Kane RC, Autio KA, Papadopoulos E, STansbury JP, Kluetz PG, Smith H, Justice R, Pazdur R. Pain Palliation Measurement in Cancer Clinical Trials: The US Food and Drug Administration

Perspective. Cancer, 2014 Mar 1;120(5):761-7. doi: 10.1002/cncr.28470. PMID: 24375398

Bennett AV, Atkinson TM, Heon N, O'Keefe B, Scheffold C, Schimoller F, Basch E. Qualitative assessment of the Brief Pain Inventory (BPI) "pain at its worst in the last 24 hours" item to support assessment of pain as a clinical trial endpoint in metastatic castrate resistant prostate cancer (mCRPC) per FDA labeling standards. Abstract. American Society of Clinical Oncology. Chicago IL, June 1-5, 2013.

Bennett AV, Eremenco S, Heon N, Scheffold C, Schimmoller F, Weitzman AL, Basch E. Mode equivalence of Interactive Voice Response (IVR) and paper versions of the Brief Pain Inventory (BPI) "worst pain" item in metastatic resistant prostate cancer (MCPRC) evaluated conceptually using qualitative methods. International Society for Pharmacoeconomics and Outcomes Research. 16th Annual European Congress, Dublin, Ireland, November 2-6, 2013.

Bennett AV, Shouery M, Wang M, Whang YE, Milowsky M, Drier S, Carr P, Morris MJ, Scher HI, Higano CS, Beer TM, Carducci MA, Basch E. Observational Longitudinal Study of Pain in Men with Metastatic Castrate-Resistant Prostate Cancer: Aim 1. Rates of pain palliation and pain progression as indicated by self-reported daily pain and analgesic use. Presentation at International Society for Quality of Life Research 25th Annual Research Meeting, Philadelphia PA, October 20, 2017.

